1989;13:545 50. 7. Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantita- tive exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005;112:I377 82. 8. Amato MC, Moffa PJ, Werner KE, et al. Treatment decision in asymptom- atic aortic valve stenosis: role of exercise testing. Heart. 2001;86:381 6. 9. Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis. 2002;11:204 9. 10. Takeda S, Rimington H, Chambers J. Prediction of symptom-onset in aortic stenosis: a comparison of pressure drop/flow slope and haemodynamic measures at rest. Int J Cardiol. 2001;81:131 7. 11. Skalski J, Allison TG, Miller TD. The safety of cardiopulmonary exercise testing in a population with high-risk cardiovascular diseases. Circulation. 2012;126:2465 72. 12. Dhoble A, Sarano ME, Kopecky SL, et al. Safety of symptom-limited car- diopulmonary exercise testing in patients with aortic stenosis. Am J Med. 2012;125:704 8. 3.2.2. Medical Therapy 1. Nazarzadeh M, Pinho-Gomes A-C, Smith Byrne K, et al. Systolic blood pressure and risk of valvular heart disease: a mendelian randomization study. JAMA Cardiol. 2019;4:788 95. 2. Rahimi K, Mohseni H, Kiran A, et al. Elevated blood pressure and risk of aortic valve disease: a cohort analysis of 5.4 million UK adults. Eur Heart J. 2018;39:3596 603. 3. Nielsen OW, Sajadieh A, Sabbah M, et al. Assessing optimal blood pres- sure in patients with asymptomatic aortic valve stenosis: the Simvastatin Ezetimibe in Aortic Stenosis study (SEAS). Circulation. 2016;134:455 68. 4. Rosseb AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with sim- vastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343 56. 5. Cowell SJ, Newby DE, Prescott RJ, et al. 